Compare NREF & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NREF | PROF |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.2M | 243.2M |
| IPO Year | N/A | 2017 |
| Metric | NREF | PROF |
|---|---|---|
| Price | $15.25 | $6.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $14.00 | $12.00 |
| AVG Volume (30 Days) | 37.9K | ★ 70.3K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 13.95% | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | $10.47 | $64.10 |
| P/E Ratio | ★ $4.78 | $35.42 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $12.36 | $3.92 |
| 52 Week High | $16.06 | $8.95 |
| Indicator | NREF | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 57.99 | 51.41 |
| Support Level | $13.76 | $5.81 |
| Resistance Level | $16.04 | $7.07 |
| Average True Range (ATR) | 0.46 | 0.43 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 52.41 | 25.57 |
NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.